Tag: familial hypercholesterolemia
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More
Zydus Lifesciences gets FDA final approval for Pitavastatin Tablets
Zydus Lifesciences said that it has bagged final approval for Pitavastatin Tablets, 1mg, 2mg, and 4mg from the US Food and Drug Administration (FDA). Pitavastatin ... Read More
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More
Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More